Fig. 6
From: The impact of CBP expression in estrogen receptor-positive breast cancer
Expression of CBP and GCN5 in clinical breast tumors. a 388 and 391 samples were analyzed by immunohistochemistry for the expression of CBP and GCN5, respectively. Samples were scored using immunoreactivity scoring system (IRS) and designated as negative (IRSā=ā0ā3), weakly positive (IRSā=ā4ā5), moderately positive (IRSā=ā6ā7) and strongly positive (IRSā=ā8ā9). b, c Immunohistochemistry analysis of b CBP and c GCN5 expressions in normal, benign lesion and breast carcinoma tissues of breast cancer patients. *pā<ā0.05, Pearson Chi-Square test. d Publicly available dataset of breast cancer patients were acquired from METABRIC database for different types of breast cancer. e The patients with ductal carcinoma (nā=ā1863) were filtrated for genetic alterations analysis of CREBBP and KAT2A genes. f, g Pie Charts for the amplification of f CREBBP gene and g KAT2A gene in ductal carcinoma patients from METABRIC database